**Question:** Which among the following is a manifestation of LCHAD deficiency?

A. Fatty liver
B. Ketoacidosis
C. Ketosis
D. Hypertriglyceridemia

**Core Concept:**
LCHAD deficiency, or long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency, is a rare genetic disorder that affects the mitochondria's ability to break down long-chain fatty acids. This leads to impaired beta-oxidation, causing toxic accumulation of long-chain fatty acids, ketone bodies, and triglycerides.

**Why the Correct Answer is Right:**
In patients with LCHAD deficiency, the deficiency of long-chain 3-hydroxyacyl-CoA dehydrogenase leads to impaired beta-oxidation of long-chain fatty acids. As a result, ketone bodies and triglycerides accumulate, leading to the manifestation of D. Hypertriglyceridemia. This is a consequence of the inability to break down these toxic substances effectively.

**Why Each Wrong Option is Incorrect:**
A. Fatty liver is not specific to LCHAD deficiency and could be seen in various other liver diseases.
B. Ketoacidosis is not a typical manifestation of LCHAD deficiency, as the primary issue is with beta-oxidation and accumulation of fatty acids, not ketone bodies.
C. Ketosis is similar to ketoacidosis but does not specifically address the impaired beta-oxidation and accumulation of fatty acids in LCHAD deficiency.

**Clinical Pearl:**
Understanding the key features of LCHAD deficiency, such as impaired beta-oxidation and accumulation of toxic substances, is crucial for accurate diagnosis and management of patients suspected to have this disorder.

**Correct Answer:** D. Hypertriglyceridemia is a direct result of impaired beta-oxidation in LCHAD deficiency, leading to the accumulation of triglycerides and their breakdown products. This is a key manifestation of the disorder and should prompt a thorough evaluation for LCHAD deficiency.